I

    Iovance Biotherapeutics Inc (IOVA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $8.17
    +0.16 (+2.00%)

    Market Cap: $3.63B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    43%(17/40)
    Avg Surprise
    -3.09%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.10
    Range$-0.12 - $-0.08
    7 analysts
    EPS Revisions
    4
    0
    7d
    4
    0
    30d
    EPS Estimate Drift
    90d ago$-0.12-29.7%
    60d ago$-0.12-29.7%
    30d ago$-0.12-28.6%
    7d ago$-0.09+7.4%
    Current$-0.10
    Revenue Consensus
    $110M
    Range$101M - $119M
    8 analysts
    Dec 31, 2026
    EPS Consensus$-0.11
    Range$-0.20 - $-0.07
    7 analysts
    Revenue Consensus
    $128M
    Range$101M - $148M
    8 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.11---
    Sep 26EST
    		-$-0.10---
    Jun 26
    		$-0.11$-0.17+35.29%Beat+66.7%
    Mar 26
    		$-0.19$-0.15-23.78%Miss+47.2%
    Dec 25
    		$-0.18$-0.18+0.00%Beat+30.8%
    Sep 25
    		$-0.25$-0.26+3.85%Beat+10.7%
    Jun 25
    		$-0.33$-0.29-13.79%Miss+2.9%
    Mar 25
    		$-0.36$-0.24-50.00%Miss+14.3%
    Dec 24
    		$-0.26$-0.27+2.84%Beat+42.2%
    Sep 24
    		$-0.28$-0.30+6.67%Beat+39.1%
    Jun 24
    		$-0.34$-0.35+2.86%Beat+27.7%
    Mar 24
    		$-0.42$-0.42+0.00%Beat+16.0%
    Dec 23
    		$-0.45$-0.43-4.65%Miss+29.7%
    Sep 23
    		$-0.46$-0.46+0.00%Beat+27.0%
    Jun 23
    		$-0.47$-0.79+40.51%Beat+25.4%
    Mar 23
    		$-0.50$-0.73+31.51%Beat+13.8%
    Dec 22
    		$-0.64$-0.64+0.00%Beat-1.6%
    Sep 22
    		$-0.63$-0.64+1.56%Beat-14.5%
    Jun 22
    		$-0.63$-0.61-3.28%Miss-18.9%
    Mar 22
    		$-0.58$-0.63+7.94%Beat-13.7%
    Dec 21
    		$-0.63$-0.56-12.50%Miss-34.0%
    Sep 21
    		$-0.55$-0.53-3.77%Miss-37.5%
    Jun 21
    		$-0.53$-0.51-3.92%Miss-12.8%
    Mar 21
    		$-0.51$-0.49-4.08%Miss+7.3%
    Dec 20
    		$-0.47$-0.44-6.82%Miss+6.0%
    Sep 20
    		$-0.40$-0.46+13.04%Beat+0.0%
    Jun 20
    		$-0.47$-0.52+9.62%Beat-23.7%
    Mar 20
    		$-0.55$-0.51-7.84%Miss-83.3%
    Dec 19
    		$-0.50$-0.42-19.05%Miss-85.2%
    Sep 19
    		$-0.40$-0.39-2.56%Miss-11.1%
    Jun 19
    		$-0.38$-0.29-31.03%Miss-11.8%
    Mar 19
    		$-0.30$-0.29-3.45%Miss+3.2%
    Dec 18
    		$-0.27$-0.26-3.85%Miss+15.6%
    Sep 18
    		$-0.36$-0.33-9.09%Miss-2.9%
    Jun 18
    		$-0.34$-0.32-6.25%Miss+8.1%
    Mar 18
    		$-0.31$-0.29-6.90%Miss-10.7%
    Dec 17
    		$-0.32$-0.32+0.00%Beat-28.0%
    Sep 17
    		$-0.35$-0.29-20.69%Miss-105.9%
    Jun 17
    		$-0.37$-0.28-32.14%Miss-
    Mar 17
    		$-0.28$-0.27-3.70%Miss-
    Dec 16
    		$-0.25$-0.25+0.00%Beat-
    Sep 16
    		$-0.17$-0.16-6.25%Miss-

    Key Metrics

    Valuation
    P/E Ratio-11.19EV/EBITDA-8.68x
    Price/FCF-12.41xFCF Yield-8.06%
    Profitability
    Profit Margin-89.10%Operating Margin-52.30%
    ROE-40.40%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio4.35xQuick Ratio3.82x
    Trading Statistics
    Beta0.70Avg Volume19.25M
    52-Week High$9.3652-Week Low$1.76

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$8.13
    SMA 20$7.14
    SMA 50$5.55
    SMA 200$3.81
    EMA 10$7.91
    EMA 20$7.26
    EMA 50$6.01
    EMA 200$4.28

    MACD

    Line: 0.86Signal: 0.85Hist: 0.01

    ADX

    ADX: 50.8+DI: 33.4-DI: 11.4

    Aroon & PSAR

    Aroon Up72.0
    Aroon Down20.0
    PSAR$9.36

    Bollinger Bands

    Upper Band$9.68
    Lower Band$4.60
    %B Position7108%(Upper)
    Band Width0.70

    RSI (14-Day)

    Neutral
    65.1

    Momentum Oscillators

    Stoch %K61.2
    Stoch %D63.8
    Williams %R-39.7
    ROC (10d)15.1%
    Momentum1.07
    CCI (20d)59.4
    MFI (14d)57.8

    Volatility Measures

    ATR (14d)$0.57(7.0%)
    StdDev (20d)1.27
    Hist Vol168.6%(High)

    Volume Flow

    VWAP$8.00
    OBV51.4M
    AD Line-195.0M
    CMF (20d)0.226

    Volume Metrics

    Avg Vol (20d)19.6M
    Vol Ratio0.6x
    VWMA (20d)$7.13

    Pivot Points

    R3$8.63
    R2$8.49
    R1$8.25
    Pivot Point$8.11
    S1$7.87
    S2$7.73
    S3$7.49

    Advanced Oscillators

    TSI37.40
    Ultimate Osc50.9
    KST688.18

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$99.31M$71.43M$86.77M$67.45M$59.95M$49.32M$73.69M$58.55M$31.11M$715,000$482,000$469,000
    Cost of Revenue$43.59M$42.50M$28.30M$38.48M$48.88M$42.72M$23.10M$31.52M$31.37M$7.26M$-5,357,000$4.34M
    Gross Profit$55.72M$28.93M$58.47M$28.98M$11.07M$6.61M$50.59M$27.04M$-262,000$-6,546,000$5.84M$-3,871,000
    Operating Expenses$107.62M$109.97M$131.93M$123.88M$124.84M$127.83M$137.17M$116.10M$101.65M$111.18M$127.09M$114.49M
    R&D$58.85M$62.49M$68.85M$75.17M$77.93M$75.97M$67.33M$67.04M$62.08M$79.78M$76.59M$87.53M
    SG&A$39.27M$38.95M$36.14M$34.55M$37.57M$43.80M$41.97M$39.34M$39.57M$31.39M$29.09M$26.96M
    Operating Income$-51,905,000$-81,043,000$-73,460,000$-94,901,000$-113,774,000$-121,221,000$-86,576,000$-89,066,000$-101,914,000$-117,722,000$-121,256,000$-118,361,000
    Interest Income$3.22M$1.33M$1.74M$1.24M$4.10M$3.22M$9.57M$4.00M$3.35M$3.34M$3.12M$3.36M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-48,688,000$-79,710,000$-71,720,000$-93,658,000$-109,670,000$-118,001,000$-77,001,000$-85,061,000$-98,559,000$-114,384,000$-118,138,000$-115,003,000
    Income Tax Expense$-1,373,000$-665,000$184,000$-2,405,000$1.99M$-1,838,000$1.56M$-1,520,000$-1,458,000$-1,408,000$-1,759,000$-1,243,000
    Net Income$-47,315,000$-79,045,000$-71,904,000$-91,253,000$-111,658,000$-116,163,000$-78,559,000$-83,541,000$-97,101,000$-112,976,000$-116,379,000$-113,760,000
    EBITDA$-42,916,000$-71,748,000$-62,158,000$-84,935,000$-103,550,000$-112,432,000$-72,184,000$-81,585,000$-93,549,000$-110,150,000$-113,269,000$-109,509,000
    EBIT$-51,905,000$-81,043,000$-73,460,000$-94,901,000$-113,774,000$-121,221,000$-86,576,000$-89,066,000$-101,914,000$-117,722,000$-121,256,000$-118,361,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IOVA

    News

    IOVA Maintained by TD Cowen -- Price Target Raised to $10.00

    Iovance Biotherapeutics Inc (IOVA) received a maintained Buy rating from TD Cowen, with analyst Nicholas Lorusso raising the price target from $7.00 to $10.00, reflecting increased confidence in the company's future. Despite this positive outlook and a current market price of $8.24, IOVA has a low GF Score™ of 34/100, indicating significant weaknesses in profitability and valuation. The company, a clinical-stage biopharmaceutical firm focusing on personalized cancer therapies, remains unprofitable with a high Price-to-Sales ratio.

    GuruFocus•8/25/26•
    Bullish

    Weekly Recap: IOVA trial updates and Mizuho raises price target to $11

    Iovance Biotherapeutics Inc (IOVA) is gaining attention due to upcoming trial data releases, including late-October SARATOGA soft-tissue sarcoma data and frontline melanoma results. Additionally, a Q4 pivotal NSCLC update and potential UK Amtagvi approval are anticipated. Mizuho has raised its price target for IOVA to $11, reflecting a revised analyst valuation.

    TradingView•8/24/26•
    Bullish

    Iovance Biotherapeutics (IOVA) Faces Investor Lawsuit Over Growth Projections Following Stock Plunge - Hagens Berman

    Iovance Biotherapeutics (NASDAQ: IOVA) is facing a securities class action lawsuit alleging that the company misled investors about its growth potential and ability to meet demand for its cancer treatments. The lawsuit claims Iovance made "overwhelmingly positive statements" while concealing "material adverse facts" regarding its readiness, leading to a significant stock price drop after a downward revision of its full-year revenue guidance. Hagens Berman is investigating these claims and encouraging affected investors to come forward.

    TMX Newsfile•8/24/26•
    Bearish

    Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates

    Iovance Biotherapeutics (IOVA) reported a Q2 loss of $0.11 per share, exceeding the Zacks Consensus Estimate of a $0.17 loss, marking a 35.29% earnings surprise. The company also surpassed revenue expectations with $99.31 million against an estimate, showing significant growth from the previous year. IOVA's stock has seen a 59% increase year-to-date, and it currently holds a Zacks Rank #2 (Buy), indicating expected market outperformance.

    Eastern Progress•8/22/26•
    Bullish

    IOVA

    This Finviz page provides a comprehensive overview of Iovance Biotherapeutics Inc. (IOVA), including its current stock performance, key financial metrics, insider and institutional ownership data, and various performance indicators. The stock closed at $8.29, experiencing a significant percentage change of -7.79% on the day. The article details market capitalization, income, sales, and a range of valuation ratios.

    Finviz•8/22/26•
    Somewhat-Bearish

    Frequently Asked Questions About IOVA

    Does IOVA pay dividends?
    Iovance Biotherapeutics Inc (IOVA) does not currently pay a regular dividend.
    What is IOVA's market cap?
    Iovance Biotherapeutics Inc (IOVA) has a market capitalization of $3.63B with a current stock price of $8.17.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In